Pharmacogenomic/pharmacokinetic assessment of a four-probe cocktail for CYPs and OATPs following oral microdosing

International Journal of Clinical Pharmacology and Therapeutics

Volumn 50, Issue 10, 2012, Pages 689-700

  Ieiri, Ichiro ^a   Fukae, Masato ^a   Maeda, Kazuya ^b   Ando, Yukie ^a   Kimura, Miyuki ^c   Hirota, Takeshi ^a   Nakamura, Takeshi ^d   Iwasaki, Kazuhide ^d   Matsuki, Shunji ^c   Matsuguma, Kyoko ^c   Kanda, Eri ^c   Deguchi, Mariko ^c   Irie, Shin ^c   Sugiyama, Yuichi ^b  

^a KYUSHU UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c Kyushu Clinical Pharmacology Research Clinic   (Japan)

^d SHIN NIPPON BIOMEDICAL LABORATORIES LTD   (Japan)

Author keywords

Cytochrome P450; OATPs; Oral microdosing; Pharmacogenomics; Pharmacokinetics

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; DEXTROMETHORPHAN; DRUG METABOLITE; GLIBENCLAMIDE; LANSOPRAZOLE; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTER 1B1; ORGANIC ANION TRANSPORTER 1B3; ORGANIC ANION TRANSPORTER 2B1; UNCLASSIFIED DRUG; WARFARIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSAGE FORM; DRUG HALF LIFE; DRUG METABOLISM; DRUG URINE LEVEL; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHARMACOGENOMICS; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUNTEER;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP2D6; DEXTROMETHORPHAN; GENOTYPE; GLYBURIDE; HUMANS; MALE; ORGANIC ANION TRANSPORTERS; WARFARIN; YOUNG ADULT;

EID: 84867253833     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201763     Document Type: Article

References (44)

1. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ. 2003; 22: 151-185. doi:10.1016/S0167-6296(02)00126-1 PubMed
2. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov. 2004; 3: 711-715. doi:10.1038/nrd1470 PubMed
3. Frank R, Hargreaves R. Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov. 2003; 2: 566-580. doi:10.1038/nrd1130 PubMed
4. Sugiyama Y, Yamashita S. Impact of microdosing clinical study - why necessary and how useful? Adv Drug Deliv Rev. 2011; 63: 494-502. doi:10.1016/j.addr.2010.09.010 PubMed
5. Combes RD, Berridge T, Connelly J, Eve MD, Garner RC, Toon S, Wilcox P. Early microdose drug studies in human volunteers can minimise animal testing: Proceedings of a workshop organised by Volunteers in Research and Testing. Eur J Pharm Sci. 2003; 19: 1-11. doi:10.1016/S0928-0987(03)00040-X PubMed
6. Chainuvati S, Nafziger AN, Leeder JS, Gaedigk A, Kearns GL, Sellers E, Zhang Y, Kashuba AD, Rowland E, Bertino JS Jr. Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail". Clin Pharmacol Ther. 2003; 74: 437-447. doi:10.1016/S0009-9236(03)00229-7 PubMed
7. Zgheib NK, Frye RF, Tracy TS, Romkes M, Branch RA. Validation of incorporating flurbiprofen into the Pittsburgh cocktail. Clin Pharmacol Ther. 2006; 80: 257-263. doi:10.1016/j.clpt.2006.06.005 PubMed
8. Krösser S, Neugebauer R, Dolgos H, Fluck M, Rost KL, Kovar A. Investigation of sarizotan's impact on the pharmacokinetics of probe drugs for major cytochrome P450 isoenzymes: a combined cocktail trial. Eur J Clin Pharmacol. 2006; 62: 277-284. doi:10.1007/s00228-006-0101-7 PubMed
9. Turpault S, Brian W, Van Horn R, Santoni A, Poitiers F, Donazzolo Y, Boulenc X. Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A. Br J Clin Pharmacol. 2009; 68: 928-935. doi:10.1111/j.1365-2125.2009.03548.x PubMed
10. Ma JD, Nafziger AN, Villano SA, Gaedigk A, Bertino JS Jr. Maribavir pharmacokinetics and the effects of multiple-dose maribavir on cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-acetyltransferase-2, and xanthine oxidase activities in healthy adults. Antimicrob Agents Chemother. 2006; 50: 1130-1135. doi:10.1128/AAC.50.4.1130-1135.2006 PubMed
11. Frye RF, Zgheib NK, Matzke GR, Chaves-Gnecco D, Rabinovitz M, Shaikh OS, Branch RA. Liver disease selectively modulates cytochrome P450-mediated metabolism. Clin Pharmacol Ther. 2006; 80: 235-245. doi:10.1016/j.clpt.2006.05. 006 PubMed
12. Satoh H, Yamashita F, Tsujimoto M, Murakami H, Koyabu N, Ohtani H, Sawada Y. Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B. Drug Metab Dispos. 2005; 33: 518-523. doi:10.1124/dmd.104. 002337 PubMed
13. Zheng HX, Huang Y, Frassetto LA, Benet LZ. Elucidating rifampin's inducing and inhibiting effects on glyburide pharmacokinetics and blood glucose in healthy volunteers: unmasking the differential effects of enzyme induction and transporter inhibition for a drug and its primary metabolite. Clin Pharmacol Ther. 2009; 85: 78-85. doi:10.1038/clpt.2008.186 PubMed
14. Ieiri I, Mamiya K, Urae A, Wada Y, Kimura M, Irie S, Amamoto T, Kubota T, Yoshioka S, Nakamura K, Nakano S, Tashiro N, Higuchi S. Stereoselective 4′-hydroxylation of phenytoin: relationship to (S)-mephenytoin polymorphism in Japanese. Br J Clin Pharmacol. 1997; 43: 441-445. doi:10.1046/j.1365-2125.1997.00572.x PubMed
15. Ieiri I, Kubota T, Urae A, Kimura M, Wada Y, Mamiya K, Yoshioka S, Irie S, Amamoto T, Nakamura K, Nakano S, Higuchi S. Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, C gamma P2C19m1 in exon 5 and C gamma P2C19m2 in exon 4, in Japanese subjects. Clin Pharmacol Ther. 1996; 59: 647-653. doi:10.1016/S0009-9236(96)90004-1 PubMed
16. Ieiri I, Yamada S, Seto K, Morita T, Kaneda T, Mamiya K, Tashiro N, Higuchi S, Otsubo KA. A CYP2D6 phenotype-genotype mismatch in Japanese psychiatric patients. Pharmacopsychiatry. 2003; 36: 192-196. doi:10.1055/s-2003-43049 PubMed
17. Nishizato Y, Ieiri I, Suzuki H, Kimura M, Kawabata K, Hirota T, Takane H, Irie S, Kusuhara H, Urasaki Y, Urae A, Higuchi S, Otsubo K, Sugiyama Y. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther. 2003; 73: 554-565. doi:10.1016/S0009-9236(03)00060-2 PubMed
18. Ieiri I, Nishimura C, Maeda K, Sasaki T, Kimura M, Chiyoda T, Hirota T, Irie S, Shimizu H, Noguchi T, Yoshida K, Sugiyama Y. Pharmacokinetic and pharmacogenomic profiles of telmisartan after the oral microdose and therapeutic dose. Pharmacogenet Genomics. 2011; 21: 495-505. doi:10.1097/FPC. 0b013e3283489ce2 PubMed
19. Ieiri I, Doi Y, Maeda K, Sasaki T, Kimura M, Hirota T, Chiyoda T, Miyagawa M, Irie S, Iwasaki K, Sugiyama Y. Microdosing clinical study: pharmacokinetic, pharmacogenomic (SLCO2B1), and interaction (Grapefruit Juice) profiles of celiprolol following the oral microdose and therapeutic dose [published online ahead of print May 18 2011]. J Clin Pharmacol. 2011, epub ahead of print. PubMed
20. Sugimoto K, Uno T, Yamazaki H, Tateishi T. Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population. Br J Clin Pharmacol. 2008; 65: 437-439. doi:10.1111/j.1365-2125.2007.03057.x PubMed
21. Beal SL, Sheiner LB. NONMEM User's Guides. San Francisco, CA: NONMEM Project Group, University of California at San Francisco; 1986.
22. Köhler D, Härtter S, Fuchs K, Sieghart W, Hiemke C. CYP2D6 genotype and phenotyping by determination of dextromethorphan and metabolites in serum of healthy controls and of patients under psychotropic medication. Pharmacogenetics. 1997; 7: 453-461. doi:10.1097/00008571-199712000-00003 PubMed
23. Chládek J, Zimová G, Beránek M, Martí nková J. In-vivo indices of CYP2D6 activity: comparison of dextromethorphan metabolic ratios in 4-h urine and 3-h plasma. Eur J Clin Pharmacol. 2000; 56: 651-657. doi:10.1007/s002280000218 PubMed
24. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther. 2008; 83: 234-242. doi:10.1038/sj.clpt.6100406 PubMed
25. Dorado P, Heras N, Machín E, Hernández F, Teran E, Llerena A. CYP2D6 genotype and dextromethorphan hydroxylation phenotype in an Ecuadorian population. Eur J Clin Pharmacol. 2012; 68: 637-644. doi:10.1007/s00228-011- 1147-8 PubMed
26. Mrazek DA, Biernacka JM, O'Kane DJ, Black JL, Cunningham JM, Drews MS, Snyder KA, Stevens SR, Rush AJ, Weinshilboum RM. CYP2C19 variation and citalopram response. Pharmacogenet Genomics. 2011; 21: 1-9. doi:10.1097/FPC. 0b013e328340bc5a PubMed
27. Kirchheiner J, Brockmöller J, Meineke I, Bauer S, Rohde W, Meisel C, Roots I. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clin Pharmacol Ther. 2002; 71: 286-296. doi:10.1067/mcp.2002.122476 PubMed
28. Yin OQ, Tomlinson B, Chow MS. CYP2C9, but not CYP2C19, polymorphisms affect the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects. Clin Pharmacol Ther. 2005; 78: 370-377. doi:10.1016/j.clpt.2005.06.006 PubMed
29. Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther. 1997; 73: 67-74. doi:10.1016/S0163-7258(96)00140-4 PubMed
30. Takahashi H, Kashima T, Nomoto S, Iwade K, Tainaka H, Shimizu T, Nomizo Y, Muramoto N, Kimura S, Echizen H. Comparisons between invitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes. Pharmacogenetics. 1998; 8: 365-373. doi:10.1097/00008571-199810000-00001 PubMed
31. Takahashi H, Kashima T, Nomizo Y, Muramoto N, Shimizu T, Nasu K, Kubota T, Kimura S, Echizen H. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes. Clin Pharmacol Ther. 1998; 63: 519-528. doi:10.1016/S0009-9236(98)90103-5 PubMed
32. Lindh JD, Holm L, Andersson ML, Rane A. Influence of CYP2C9 genotype on warfarin dose requirements - a systematic review and meta-analysis. Eur J Clin Pharmacol. 2009; 65: 365-375. doi:10.1007/s00228-008-0584-5 PubMed
33. Dayer P, Leemann T, Striberni R. Dextromethorphan O-demethylation in liver microsomes as a prototype reaction to monitor cytochrome P-450 db1 activity. Clin Pharmacol Ther. 1989; 45: 34-40. doi:10.1038/clpt.1989.6 PubMed
34. Evans WE, Relling MV, Petros WP, Meyer WH, Mirro J Jr, Crom WR. Dextromethorphan and caffeine as probes for simultaneous determination of debrisoquin-oxidation and N-acetylation phenotypes in children. Clin Pharmacol Ther. 1989; 45: 568-573. doi:10.1038/clpt.1989.74 PubMed
35. Tateishi T, Chida M, Ariyoshi N, Mizorogi Y, Kamataki T, Kobayashi S. Analysis of the CYP2D6 gene in relation to dextromethorphan O-demethylation capacity in a Japanese population. Clin Pharmacol Ther. 1999; 65: 570-575. doi:10.1016/S0009-9236(99)70077-9 PubMed
36. Yoon YR, Cha IJ, Shon JH, Kim KA, Cha YN, Jang IJ, Park CW, Shin SG, Flockhart DA, Shin JG. Relationship of paroxetine disposition to metoprolol metabolic ratio and CYP2D6*10 genotype of Korean subjects. Clin Pharmacol Ther. 2000; 67: 567-576. doi:10.1067/mcp.2000.106128 PubMed
37. Sohn DR, Kwon JT, Kim HK, Ishizaki T. Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4′-hydroxylation phenotype status. Clin Pharmacol Ther. 1997; 61: 574-582. doi:10.1016/S0009-9236(97)90137- 5 PubMed
38. Ieiri I, Kishimoto Y, Okochi H, Momiyama K, Morita T, Kitano M, Morisawa T, Fukushima Y, Nakagawa K, Hasegawa J, Otsubo K, Ishizaki T. Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism. Eur J Clin Pharmacol. 2001; 57: 485-492. doi:10.1007/s002280100342 PubMed
39. Tanaka M, Ohkubo T, Otani K, Suzuki A, Kaneko S, Sugawara K, Ryokawa Y, Hakusui H, Yamamori S, Ishizaki T. Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4′-hydroxylation phenotype and genotype. Clin Pharmacol Ther. 1997; 62: 619-628. doi:10.1016/S0009-9236(97)90081-3 PubMed
40. Gawrońska-Szklarz B, Adamiak-Giera U, Wyska E, Kurzawski M, Gornik W, Kaldonska M, Drozdzik M. CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers. Eur J Clin Pharmacol. 2012. Epub ahead of print. PubMed
41. Nambu T, Hamada A, Nakashima R, Yuki M, Kawaguchi T, Mitsuya H, Saito H. Association of SLCO1B3 polymorphism with intracellular accumulation of imatinib in leukocytes in patients with chronic myeloid leukemia. Biol Pharm Bull. 2011; 34: 114-119. doi:10.1248/bpb.34.114 PubMed
42. Lappin G, Kuhnz W, Jochemsen R, Kneer J, Chaudhary A, Oosterhuis B, Drijfhout WJ, Rowland M, Garner RC. Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. Clin Pharmacol Ther. 2006; 80: 203-215. doi:10.1016/j.clpt.2006.05.008 PubMed
43. Mamidi RN, Satyavageeswaran S, Vakkalanka SV, Chaluvadi MR, Katneni K, Brahmadevara N, Damodarram G, Subramaniam S. Polymorphism of dextromethorphan oxidation in South Indian subjects. Clin Pharmacol Ther. 1999; 66: 193-200. PubMed
44. Basci NE, Bozkurt A, Kayaalp SO, Sayal A, Isimer A. Omission of the deconjugation step in urine analysis and the unaltered outcome of CYP2D6 phenotyping with dextromethorphan. Eur J Drug Metab Pharmacokinet. 1998; 23: 1-5. doi:10.1007/BF03189819 PubMed